Regulation of endocytosis via the oxygen-sensing pathway

Yi Wang; Roche, Olga; Yan, Mathew S.; Finak, Greg; Evans, Andrew J.; Metcalf, Julie L.; Hast, Bridgid E.; Hanna, Sara C.; Wondergem, Bill; Furge, Kyle A.; Irwin, Meredith S.; Kim, William Y.; Teh, Bin T.; Grinstein, Sergio; Park, Morag; Marsden, Philip A.; Ohh, Michael
March 2009
Nature Medicine;Mar2009, Vol. 15 Issue 3, p319
Academic Journal
Tumor hypoxia is associated with disease progression, resistance to conventional cancer therapies and poor prognosis. Hypoxia, by largely unknown mechanisms, leads to deregulated accumulation of and signaling via receptor tyrosine kinases (RTKs) that are critical for driving oncogenesis. Here, we show that hypoxia or loss of von Hippel–Lindau protein—the principal negative regulator of hypoxia-inducible factor (HIF)—prolongs the activation of epidermal growth factor receptor that is attributable to lengthened receptor half-life and retention in the endocytic pathway. The deceleration in endocytosis is due to the attenuation of Rab5-mediated early endosome fusion via HIF-dependent downregulation of a critical Rab5 effector, rabaptin-5, at the level of transcription. Primary kidney and breast tumors with strong hypoxic signatures show significantly lower expression of rabaptin-5 RNA and protein. These findings reveal a general role of the oxygen-sensing pathway in endocytosis and support a model in which tumor hypoxia or oncogenic activation of HIF prolongs RTK-mediated signaling by delaying endocytosis-mediated deactivation of receptors.


Related Articles

  • Controlling Receptor Downregulation by Ubiquitination and Deubiquitination. Komada, Masayuki // Current Drug Discovery Technologies;Mar2008, Vol. 5 Issue 1, p78 

    Growth factor-activated receptor tyrosine kinases (RTKs) undergo rapid endocytosis and degradation in lysosomes. This process, known as receptor downregulation, is essential to prevent the overgrowth of cells by terminating signal transduction from activated RTKs. Thus, defects in RTK...

  • Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies. Daniele, Lorenzo; Sapino, Anna // Recent Patents on Anti-Cancer Drug Discovery;Jan2009, Vol. 4 Issue 1, p9 

    HER2 is a transmembrane tyrosine kinase receptor in the EGFR (epidermal growth factor receptor) family. The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence,...

  • HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Gusenbauer, S; Vlaicu, P; Ullrich, A // Oncogene;8/15/2013, Vol. 32 Issue 33, p3846 

    The epidermal growth factor receptor (EGFR) is overexpressed and activated in many human cancers and predicts poor patient prognosis. Targeting the kinase domain with specific EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib has been used in anticancer treatments. However,...

  • EGFRs: New class of cancer therapy on the horizon. LoBuono, Charlotte // Drug Topics;11/4/2002, Vol. 146 Issue 21, p20 

    Discusses the role of epidermal growth factor receptor (EGFR) in the uncontrolled growth of severe human cancers. Inhibition of apoptosis; Autophosphorylation of specific tyrosine residues of the EGFR due to dimerization; Three EGFR-tyrosine kinase inhibitors.

  • Outcome of Patients with Lung Adenocarcinoma Harboring Common and Rare Epidermal Growth Factor Receptor Mutations in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. AMIEVA-RIVERA, EDUARDO; MARTÍNEZ-HERNÁNDEZ, JORGE NEGUEB; LOPEZ-MEJÍA, MARIANA; DE LA GARZA-SALAZAR, JAIME; ARRIETA-RODRÍGUEZ, ÓSCAR // Journal of Cancerology;Apr-Jun2015, Vol. 2 Issue 2, p56 

    Background: Approximately 10-40% of patients with adenocarcinoma have somatic mutations in the epidermal growth factor receptor. The presence of the common activating epidermal growth factor receptor mutations (DEL 19/L858R) is closely associated with sensitivity to reversible tyrosine kinase...

  • Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review. Moreira, Irina Sousa; Fernandes, Pedro Alexandrino; Ramos, Maria Joao // Anti-Cancer Agents in Medicinal Chemistry;2007, Vol. 7 Issue 2, p223 

    Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important...

  • Optimizing Anti-EGFR Strategies in Cancer Treatment. Toschi, Luca; Finocchiaro, Giovanna; Garassino, Isabella; De Vincenzo, Fabio; Campagnoli, Elizabetta; Ceresoli, Giovanni Luca; Cavina, Raffaele; Zucali, Paolo Andrea; Santoro, Armando; Cappuzzo, Federico // Current Cancer Therapy Reviews;2007, Vol. 3 Issue 4, p267 

    Molecules interfering with the Epidermal Growth Factor Receptor (EGFR) have been successfully tested in several human malignancies in the last decade, including non-small cell lung cancer, colo-rectal, pancreatic and head and neck cancer. Particularly, the two most commonly used strategies for...

  • Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. Schettino, Clorinda; Bareschino, Maria Anna; Maione, Paolo; Rossi, Antonio; Ciardiello, Fortunato; Gridelli, Casare // Current Cancer Therapy Reviews;2007, Vol. 3 Issue 4, p226 

    The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity which plays a key role in human cancer. EGFR-dependent signaling is involved in cancer cell proliferation, apoptosis, angiogenesis, invasion and metastasis. Targeting the EGFR...

  • Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy. Ruggeri, B.; Underiner, T. L.; Gingrich, D. E. // Current Medicinal Chemistry;Mar2004, Vol. 11 Issue 6, p731 

    Among the known angiogenic growth factors and cytokines implicated in the modulation of normal and pathological angiogenesis, the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF-D) and their corresponding receptor tyrosine kinases [VEGFR-1 (Flt-1), VEGFR-2 (Flk-1, KDR), and VEGFR-3 (Flt-4)] play a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics